Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)

  1. Jódar, E.
  2. Michelsen, M.
  3. Polonsky, W.
  4. Réa, R.
  5. Sandberg, A.
  6. Vilsbøll, T.
  7. Warren, M.
  8. Harring, S.
  9. Ziegler, U.
  10. Bain, S.
Aldizkaria:
Diabetes, Obesity and Metabolism

ISSN: 1463-1326,  1462-8902

Argitalpen urtea: 2020

Alea: 22

Zenbakia: 8

Orrialdeak: 1339-1347

Mota: Artikulua

DOI: 10.1111/DOM.14039 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus